Adriana De Siervi

Transcripción

Adriana De Siervi

Adriana De Siervi
Laboratorio de Oncología Molecular y Nuevos Blancos Terapéuticos,
Instituto de Biología y Medicina Experimental (IBYME) - CONICET
http://www.ibyme.org.ar/laboratorios/44/oncologia-molecular-y-nuevos-blancosterapeuticos
Vuelta de Obligado 2790, 1428ADN - Capital Federal - Argentina
E-mail: [email protected]
Phone: +5411-4783-2869 ext. 206 y Mobil: 15-3269-5832
Present Position
Independent Investigator (CONICET)
Lab chief at Laboratory of Molecular Oncology and New Therapeutic Targets –
Instituto de Biología y Medicina Experimental (IBYME) Buenos Aires, Argentina.
Education
1993 M.S. Biology (FCEN-UBA).
1998 Ph.D. in Molecular Biology (FCEN-UBA). Doctoral thesis: “Molecular
genetic of the Acute Intermittent Porphyria: First study in the Argentinean
population”. Mentor: Prof. Dra. María Victoria Rossetti.
2001-2006
Postdoct at National Institutes of Health (NIH – USA).
Research positions and employment
1994-1998
Ph.D. student: Porphyrins and Porphyrias Research Center
(CIPYP). CONICET, School of Sciences (FCEyN), University of
Buenos Aires (UBA). Argentina. Initiation and improvement
fellowships (CONICET).
1996
Invited Scientist: Department of Human Genetic, Mount Sinai
Medical School, New York, USA. “Detection, identification and
expression of mutations in Argentinean patients with Acute
Intermittent Porphyria”. Mentor: Dr. Robert Desnick.
1998-2001
Post-doctoral fellowship from CONICET at the CIPYP, FCEN, UBA,
Argentina. “Molecular genetics of Acute Porphyrias. Studies
about the association with hepatocellular cáncer”. Mentor: Prof.
Dr. Alcira Batlle.
2001-2003
Postdoctoral fellowship from Fogarty at the Oral and Pharyngeal
Cancer Branch (OPCB), National Institute of Dental and
Craniofacial Research (NIDCR), National Institutes of Health
(NIH), USA. “Mechanism of action of chemotherapy drugs:CDK
inhibitors”. Mentor: Dr. Adrián Senderowicz.
2003-2006
Postdoctoral fellowship from Fogarty at the Laboratory of
Receptor Biology & Gene Expression, National Cancer Institute
(NCI), NIH, USA. “Transcription and cancer”. Mentor: Dr. Kevin
Gardner.
Curriculum vitae Adriana De Siervi 2016
1
2006
2007-2012
Re-insertion fellowship from CONICET until obtains investigator
position at the same Council, Laboratory of Apoptosis and
Cancer, Department of Biological Chemistry, School of Sciences
(FCEyN), University of Buenos Aires (UBA). Argentina.
Associate Investigator from the CONICET, Laboratory of Apoptosis
and Cancer, Department of Biological Chemistry, School of
Sciences (FCEyN), University of Buenos Aires (UBA). Argentina.
2012-2013 Independent Investigator from the CONICET, Laboratory of
Apoptosis and Cancer, Department of Biological Chemistry,
School of Sciences (FCEyN), University of Buenos Aires (UBA).
Argentina.
2013-present Independent Investigator (CONICET) Head of the Laboratory of
Molecular Oncology and New Therapeutic Targets – Institute of
Biology and Experimental Medicine (IBYME) Buenos Aires,
Argentina.
Honors
2002. NIDCR Award: NIH (USA), in recognition of outstanding achievements in
oral health and craniofacial research.
2008. Irene Faryna Award (Mar del Plata, Argentina) for the best scientific work
in oncology field: Gueron, G; Ferrando, M; Salierno, M; De Luca, P; De
Siervi, A; Vazquez, E. “Rol crítico de la expresión de hemo oxigenasa 1
(HO-1) como un modulador del potencial invasivo de células de cáncer
de próstata”.
2009. AACR award (USA): Prostate Cancer Foundation– Prostate Cancer
recognition award presented to promising young cancer researchers
who are the first authors and of highly rated proffered papers focused
on advance/late prostate cancer research, American Association 100th
Annual Meeting 2009: “Critical role of endogenous heme oxygenase 1
(HO-1) as a turner of the invasive potential of prostate cancer in vitro
and in vivo through MMP9 modulation”. G. Gueron, M. Ferrando, M.
Salierno, P. De Luca, B. Elguero, R. Meiss, A. De Siervi, N. Navone, E.
Vazquez.
2010. AACR-AstraZeneca International Scholar-in-Training Award, American
Association 101st Annual Meeting 2010: “Nuclear translocation of HO-1
in Prostate cancer. Role beyond heme degradation”. G. Gueron, M.
Ferrando, B. Elguero, A. Salles, R. Meiss, L. Colombo, A. Curino, MM.
Facchinetti, N. Navone, A. De Siervi, E. Vazquez.
2012. Award: ATM transcriptional regulation mediated by BRCA1/E2F1 axis controls
DNA damage response in prostate cancer. Authors: Moiola C, De Luca P,
Zalazar F, Cotignola J, Gardner K, Vazquez E, De Siervi A. Selected abstract
from the top 5% best posters presented at 103rd Annual Meeting American
2
Association for Cancer Research AACR (Chicago, USA, March 31st to April
4th 2012). Proc. AACR (2012) 53: p.270. Abstract: 1312 (poster).
2013. Award MONTOURI-FUNDACION GADOR at oncology field: CtBP1 is a
molecular metabolic switch that mediates prostate tumor development
dependent of high-fat diet. Authors: Moiola C, De Luca P, Zalazar F,
Cotignola J, Meiss R, Vallecorsa P, Mazza O, Scorticati C, Paz D, Pignataro
O, Vazquez E, De Siervi A. LVIII Reunión Científica Anual de la SAIC (Mar
del Plata, Buenos Aires, Argentina) November 20th – 23rd 2013. Medicina.
Amount: U$2.000.
Grants
PICT 2015 (1345) Plan Argentina Innovadora 2020: Molecular studies that
associates metabolic syndrome and breast and prostate cancer
development. Amount: U$90.000. Ongoing.
PICT 2014 (324) Plan Argentina Innovadora 2020: MicroRNAs: new molecular
tools for early diagnosis and therapy against cancer in a metabolic
syndrome animal model. Amount: U$60.000. Ongoing.
PICT 2012 (374), PI: Molecular studies that associates hipercaloric diet and
breast and prostate tumor development. Amount: $70.000. Ongoing.
Financial assistance to cancer projects from National Cancer Institute (Argentina)
2012-2014: Molecular studies that associates obesity and breast and
prostate cancer risks. Amount: U$40.000. Ongoing.
PICT RAICES 2010-2013 (431), Co-PI: Nuclear localization of Heme
Oxygenase 1 (HO1) in prostate cancer: a function beyond heme
degradation. PI Dr. Elba Vazquez. Amount: U$90,000. Expired.
PICT RAICES 2006-2009 (367), Co-PI: HO1 and VEGF role in bone
metastasis from prostate cancer.
PI Dr. Elba Vazquez. Amount:
U$90,000. Expired.
UBACYT (X230), Co-investigator: HO1 and VEGF role in bone metastasis
from prostate cancer. PI Dr. Elba Vazquez. Amount: U$20,000. Expired.
PICT 2006-2009 (228), PI: BRCA1 role in prostate cancer. Amount:
U$90,000. Expired.
Research in Molecular Biology and proteomics grant from ORT school (2007).
Amount: U$1,000. Expired.
Mentor of undergraduate students:
1. Débora Weiss Cádiz (03/1999 - 03/2000) FCEN, UBA, Argentina.
2. Carolina Rezaval (03/2000 - 10/2000) FCEN, UBA, Argentina.
3. Terence Sy (08/2001 - 08/2002) NIDCR, NIH, USA.
4. Doreen Toskos (06/2002 - 09/2002) NIDCR, NIH, USA.
5. Carol Hwang (03/2002 - 03/2003) NIDCR, NIH, USA.
6. Violet Fernandez (03/2003 - 11/2003) NIDCR, NIH, USA.
3
7. Andrea Graham (06/2003 - 11/2003) NIDCR, NIH, USA.
Mentor of undergraduate thesis
1. Marina Ruiz Grecco (14/3/2008) FCEN, UBA. Director. Qualification: 10.
2. Mercedes Ferrando (20/3/2008) FCEN, UBA. Co-director. Qualification: 10.
3. Julián Chamorro (11/2008) FCEN, UBA. Director. Qualification: 10.
4. Florencia Zalazar (18/3/2009) FCEN, UBA. Director. Qualification: 10.
5. Federico Aranda (14/4/2009) FCEN, UBA. Co-director. Qualification:10.
6. Estefanía Labanca (11/4/2014) FCEN, UBA. Director. Qualification: 10.
7. Nicolás Dalton (19/12/2013) FCEN, UBA. Director. Qualification: 10.
Mentor of doctoral thesis:
1. Paola De Luca (1/04/07 - 29/12/11) FCEN, UBA. Director. Qualification:
Oustanding.
2. Cristian Moiola (1/7/2008 - 18/03/2013) FCEN, UBA. Director.
Qualification: Oustanding.
3. Belén Elguero (1/10/2008 - 28/05/2013) FCEN, UBA. Director.
4. Florencia Zalazar (1/4/09 - 11/05/2015) FCEN, UBA. Director.
5. Nicolás Dalton (1/5/2014 – ongoing) IBYME – CONICET.
6. Cintia Massillo (1/6/2014 – ongoing) IBYME – CONICET.
7. Juliana Porretti (1/7/2014 – ongoing) IBYME – CONICET.
Mentor of post-doctoral fellowship:
Paola De Luca (1/4/2012- 30/9/2014) Postdoctoral fellow CONICET. FCEN,
UBA; IBYME.
Cristian Moiola (1/4/2013- 1/02/2015) Postdoctoral fellow CONICET. FCEN,
UBA; IBYME.
Mentor of investigators
Javier Cotignola (11/2009 – 11/2015) Co-director, assistant investigator
CONICET. FCEN – UBA.
Paola De Luca (1/10/2014- ongoing) Director, assistant investigator CONICET.
IBYME.
Mentor of masters
Maria Luz Pujol (1/2/2014 - 30/9/2014) Microfluidic and Biological
Engineering, Department of Microsystems Engineering–IMTEK, Centre for
Biological Signalling Studies-BIOSS (University of Freiburg, Germany). Codirector.
Mentor of doctoral fellowship
Paola De Luca, director CONICET type I and II fellow from 1/04/07 to
31/3/2012 Departamento de Química Biológica, FCEN – UBA.
Cristian Moiola, director CONICET type I and II fellow from 1/7/08 to 31/3/13
Departamento de Química Biológica, FCEN – UBA.
Mercedes Ferrando, co-director CONICET type I and II fellow from 1/04/08 to
31/3/2012 Departamento de Química Biológica, FCEN – UBA. Director: Dra.
Elba Vazquez.
4
Belén Elguero, co-director CONICET type I and II fellow from 1/10/08 to
31/3/2013 Departamento de Química Biológica, FCEN – UBA. Director: Dra.
Elba Vazquez.
Florencia Zalazar, director CONICET type I and II fellow from 1/04/09 to
31/3/2014 Departamento de Química Biológica, FCEN – UBA.
Nicolás Dalton, director ANPYCT fellowship from 1/5/14
Laboratorio de
Oncología Molecular y Nuevos Blancos Terapéuticos (IBYME, CONICET).
Ongoing.
Cintia Massillo, director CONICET fellowship from 1/6/14 Laboratorio de
Ongoing.
Juliana Porretti, director CONICET fellowship from 1/6/14 Laboratorio de
Ongoing.
Georgina Daniela Scalise director INC fellowship from 1/8/16 Laboratorio de
Ongoing.
Member of review committee
Reviewed 11 Doctoral Thesis, Universidad de Buenos Aires, Argentina.
Reviewed 10 Undergraduate Thesis, Universidad de Buenos Aires, Argentina.
Reviewed 2 Master Thesis, Universidad de Buenos Aires, Argentina.
Professional memberships and reviewer
2008-present: Active member of the American Association for Cancer Research
(AACR), USA.
2008-present: Active member of the Argentinean Society of Clinical Investigation
(SAIC), Argentina.
2009-present: Reviewer of several argentinean grant applications for the
National Agency of Science and Technology (ANPYCT), Argentina.
2011: Coordinator of poster session at the meeting of Sociedad Argentina de
Investigación Clínica (SAIC), Argentina.
2011: Reviewer
(Holland).
of
one
grant
application
from
Dutch
Cancer
Society
2011-present: reviewer of manuscripts to be consider at: Cancer Research
(AACR), Cellular Physiology and Biochemistry (Ed KARGER), Cell Cycle
(Ed Landes Bioscience), Frontiers in Bioscience (Ed Landmark), Frontiers
in Oncology (Ed Nature Publishing Group), Tumor Biology (Ed Springer),
Journal of Investigative Dermatology (Ed Nature Publishing Group),
Oncogene (Ed Nature Publishing Group), Asian Journal of Andrology (Ed
Asian Society of Andrology), Tumori (Istituto Nazionale dei Tumori), PLOS
one (PLOS), JAMA Oncology (Ed JAMA), Molecular Cancer Therapeutics
(Ed AACR), Journal of Translational Medicine (Ed BioMed central), Cancer
5
Biology and Medicine (Ed Chinese Anticancer Association), Oncotarget
(Editorial Impact Journal).
2012-present: Reviewer for investigator promotions from CONICET, Argentina.
2012-present: Reviewer of one grant for National Agency Research from Uruguay
(ANII) Fondo María Viñas 2011 (FMV 2011).
2012-present: Managing Editor from Frontiers in Bioscience (Landmark).
2013-present: Review Editor from Frontiers in Oncology, Ed. Nature Publishing
Group.
Teaching
1995. Teaching assistant for undergraduate
Medicine, University of Buenos Aires.
student
course,
School
of
1996-1998. Graduate Teaching Assistant for graduate student course: Molecular
diagnosis in medicine. National Research Institute on Porphyrins and
Porphyrias (CIPYP), School of Sciences, University of Buenos Aires.
2006-present. Presentation of one lecture: “Transcription factors with oncogenic
properties” at the graduate students course: “Apoptosis and cancer:
molecular and cellular basis” , Dr. Elba Vazquez, FCEN, University of Buenos
Aires.
2008-present. Presentation of two lectures: “Transcription factors and cancer”
“MiRNAs in cancer: from básic to clinical research” at the graduate students
course: “Carcinogenesis”, Dr. Claudia Lanari, IBYME, CONICET.
2010-present. Organization of seminar series of the Department of Biological
Chemistry, FCEN, UBA, together with Dr. Cybele Garcia.
Lecture presentations
Oral and Pharyngeal Cancer Branch, National Institute of Dental and Craniofacial
Research, NIH, USA. “Transcriptional activation of p21WAF1 by Perifosine”.
March 2003.
Laboratory of Biology Receptor and Gene Expression, National Cancer Institute,
NIH, USA. “Transcriptional activation of p21WAF1 by Perifosine”. November
2003.
Genitourinary Medical Oncology Seminar series, M D Anderson, Houston,
Texas, USA. “Transcriptional activation of p21WAF1 by Perifosine”. March
2005.
Laboratory of Biology Receptor and Gene Expression, National Cancer Institute,
NIH, USA. “BRCA1 assembles a repressive protein complex at its own
promoter”. March 2006.
American Association for Cancer Research (AACR) San Diego, CA, USA. BRCA1
regulates GADD153-mediated apoptosis in prostate cancer cells. April 2008.
6
Seminar series of the Department of Biological Chemistry, FCEyN – UBA.
“BRCA1 role in the regulation of transcription.” June 2008.
Seminar series of the IIB – University of San Martin (UNSAM). “Studies about
cell cycle regulators, tumor suppressors and oncogenes involve in
progression and prostate cancer therapy.” April 2011.
Seminar series IBYME. Molecular studies that associates obesity with breast and
prostate cancer risk. May 2012.
Publications
1.
Leonardi DB, Abbate M, Riccheri MC, Nuñez M, Alfonso G, Gueron G, De Siervi A,
Vazquez E, Cotignola J. Improving risk stratification of patients with childhood acute
lymphoblastic leukemia: Glutathione-S-Transferases polymorphisms are associated
with increased risk of relapse. Oncotarget. 2016 doi: 10.18632/oncotarget.8606. In
press.
2.
De Luca P, Dalton GN, Scalise GD, Moiola CP, Porretti J, Massillo C, Kordon E, Gardner
K, Zalazar F, Flumian C, Todaro L, Vazquez ES, Meiss R, De Siervi A. CtBP1
associates metabolic syndrome and breast carcinogenesis targeting multiple miRNAs.
Oncotarget. 2016. 7(14):18798-811.
3.
De Luca P, De Siervi A. Critical role for BRCA1 expression as a marker of
chemosensitivity response and prognosis. Frontiers in Bioscience. 2016. 8:72-83.
4.
Labanca E, De Luca P, Gueron G, Paez A, Moiola CP, Massillo C, Porretti J, Giudice J,
Zalazar F, Navone N, Vazquez E, De Siervi A. Association of HO-1 and BRCA1 is
Critical for the Maintenance of Cellular Homeostasis in Prostate Cancer. Mol Cancer
Res. 2015. 13(11):1455-64.
Highlighted in the issue of the journal.
5.
Zalazar F, De Luca P, Gardner K, Figg WD, Meiss R; Spallanzani RG; Vallecorsa P;
Elguero B; Cotignola J; Vazquez E & De Siervi A. Low doses of CPS49 and flavopiridol
combination as potential treatment for advanced prostate cancer. Curr Pharm
Biotechnol. 2015. 16(6):553-63.
6.
Moiola CP, De Luca P, Zalazar F, Cotignola J, Rodriguez-Segui S, Gardner K, Meiss R,
Vallecorsa P, Pignataro O, Mazza O, Vazquez ES, De Siervi A. Prostate tumor growth
is impaired by CtBP1 depletion in high fat diet fed mice. Clinical Cancer Research.
2014. 20(15):4086-95.
7.
Ferrando M, Wan X, Meiss R, Yang J, De Siervi A, Navone N, Vazquez E. Heme
Oxygenase-1 (HO-1) Expression in Prostate Cancer Cells Modulates the Oxidative
Response in Bone Cells. PLoS One. 2013;8(11):e80315.
8.
De Luca P, Moiola C, Zalazar F, Gardner K, Vazquez E & De Siervi A. BRCA1 and p53
regulate critical prostate cancer pathways. Prostate Cancer and Prostatic Diseases.
16(3):233-8. (2013)
9.
Palm T, Hemmer K, Winter J, Fricke I, Tarbashevich K, Sadeghi Shakib F, Rudolph IM,
Hillje AL, De Luca P, Bahnassawy L, Madel R, Viel T, De Siervi A, Jacobs A, Diederichs
S, Schwamborn J. A systemic transcriptome analysis reveals the regulation of neural
stem cell maintenance by an E2F1-miRNA feedback loop. Nucleic Acids Research.
41(6):3699-3712 (2013).
7
10. Cotignola J, Leonardi D, Shahabi A, Acuña A, Stern M, Navone N, Scorticati C, De
Siervi A, Mazza O & Vazquez E. Glutathione-S-Transferase (GST) polymorphisms are
associated with relapse after radical prostatectomy. Prostate Cancer & Prostatic
Diseases. 16(1):28-34. (2013).
11. Elguero B, Gueron G, Giudice J, Toscani M, De Luca P, Zalazar F, Coluccio-Leskow F,
Meiss R, Navone N, De Siervi A & Vazquez E. Unveiling the Association of STAT3 and
HO-1 in Prostate Cancer : Role beyond Heme Degradation. Neoplasia. 14(11):104356. (2012).
12. Moiola C, De Luca P, Cotignola J, Gardner K, Vazquez E & De Siervi A. Dynamic
coregulatory complex containing BRCA1, E2F1 and CtIP controls ATM transcription.
Cellular Physiology and Biochemistry. 30(3):596-608. (2012).
13. Gueron G, De Siervi A, Vazquez E. Advanced prostate cancer: reinforcing the strings
between inflammation and the metastatic behavior. Prostate Cancer & Prostatic
Diseases. 15(3):213-21 (2012).
14. Ferrando M, Gueron G, Elguero B, Giudice J, Salles A, Leskow FC, Jares-Erijman EA,
Colombo L, Meiss R, Navone N, De Siervi A, Vazquez E. Heme oxygenase 1 (HO-1)
challenges the angiogenic switch in prostate cancer. Angiogenesis. 14(4):467-479
(2011).
15. De Luca P, Vazquez E, Moiola C, Zalazar F, Cotignola J, Gueron G, Gardner K & De
Siervi A. BRCA1 loss induces GADD153-mediated doxorubicin resistance in prostate
cancer. Mol. Cancer Res. 9(8):1078-90 (2011).
16. Gueron G, De Siervi A & Vazquez E. Key Questions in Metastasis: New Insights in
Molecular Pathways and Therapeutic Implications. Curr Pharm Biotechnol. 12: 186780 (2011). Invitación para escribir un review.
17. Di LJ, Fernandez AG, De Siervi A, Longo D & Gardner K. Transcriptional regulation of
BRCA1 expression by a metabolic switch. Nat. Struct. & Mol. Biol. 17: 1406–1413
(2010).
Highlighted at NCI, NIH-USA web site:
http://www.cancer.gov/newscenter/pressreleases/BRCA1proteinobesity
Highlighted in the journal
http://www.nature.com/nsmb/journal/v17/n12/index.html#rhighlts
18. Moiola C, De Luca P, Gardner K, Vazquez E & De Siervi A. Cyclin T1 overexpression
induces malignant transformation and tumor growth. Cell cycle. 9(15):3119-26
(2010).
19. De Siervi A, De Luca P, Byun JS, Di LJ, Fufa T, Haggerty CM, Vazquez E, Moiola C,
Longo DL, Gardner K. Transcriptional autoregulation by BRCA1. Cancer Res.
70(2):532-42 (2010).
20. Gueron G, De Siervi A, Ferrando M, Salierno M, De Luca P, Elguero B, Meiss R,
Navone N, Vazquez ES. Critical role of endogenous heme oxygenase 1 as a tuner of
the invasive potential of prostate cancer cells. Mol Cancer Res. 7(11):1745-55 (2009).
21. Byun JS, Wong MM, Cui W, Idelman G, Li Q, De Siervi A, Bilke S, Haggerty CM, Player
A, Wang YH, Thirman MJ, Kaberlein JJ, Petrovas C, Koup RA, Longo D, Ozato K,
Gardner K. Dynamic bookmarking of primary response genes by p300 and RNA
polymerase II complexes. Proc Natl Acad Sci USA. 106(46):19286-91 (2009).
22. De Siervi A, De Luca P, Moiola C, Gueron G, Tongbai R, Chandramouli GV, Haggerty
C, Dzekunova I, Petersen D, Kawasaki E, Kil WJ, Camphausen K, Longo D, Gardner K.
8
Identification of new Rel/NFkappaB regulatory networks by focused genome location
analysis. Cell Cycle. 8(13):2093-100 (2009).
23. Macias E, Miliani de Marval PL, De Siervi A, Conti CJ, Senderowicz AM, RodriguezPuebla ML. CDK2 activation in mouse epidermis induces keratinocyte proliferation but
does not affect skin tumor development. Am J Pathol. 173(2):526-35 (2008).
24. Ge Y, Byun JS, De Luca P, Gueron G, Li QQ, Yabe IM, Sadiq-Ali SG, Figg WD, Quintero
J, Haggerty CM, De Siervi A, Gardner K. Combinatorial anti-leukemic disruption of
oxidative homeostasis and mitochondrial stability by the redox reactive thalidomide
CPS49 and flavopiridol. Mol Pharmacol. 74(3):872-83 (2008).
25. Smith J, Freebern WJ, Collins I, De Siervi A, Montano I, Haggerty CM, McNutt MC,
Butscher WG, Dzekunova I, Petersen DW, Kawasaki E, Merchant JL, Gardner K. Kinetic
profiles of p300 occupancy in vivo predict common features of promoter structure and
coactivator recruitment. Proc Natl Acad Sci USA. 101(32):11554-11559 (2004).
26. De Siervi A, Marinissen MJ, Diggs J, Wang X-F, Pages Gilles & Senderowicz AM
Transcriptional activation of p21waf1/cip1 by alkylphospholipids. Role of the MAPK
pathway in the transactivation of the human p21 waf1/cip1 promoter by Sp1. Cancer Res
64:743-750 (2004).
27. Facchinetti MM, De Siervi A, Toskos D & Senderowicz AM UCN-01-induced cell cycle
arrest requires the transcriptional induction of p21(waf1/cip1) by activation of
mitogen-activated protein/extracellular signal-regulated kinase kinase/extracellular
signal-regulated kinase pathway. Cancer Res. 64(10):3629-3637 (2004).
28. Lahusen T*, De Siervi A*, Kunick C & Senderowicz A. Alsterpaullone, a novel cyclindependent kinase inhibitor, induces apoptosis by activation of caspase 9 due to
perturbation in mitochondrial membrane potential. Mol Carcinogenesis. 36(4):183-94
(2003).
29. Parera VE, De Siervi A, Varela L, Rossetti MV, Batlle AM. Acute porphyrias in the
Argentinean population: a review. Cell Mol Biol 49(4):493-500 (2003).
30. De Siervi A, Vazquez E, Rezaval C, Rossetti MV & Batlle A. -aminolevulinic acid
cytotoxic effects on human hepatocarcinoma cell lines. BioMed Central cancer 2:6
(2002).
31. De Siervi A, Varela LS, Parera VE, Batlle A & Rossetti MV. Diagnosis of latent acute
intermittent porphyria by genetic analysis. Ann Clin Biochem. 38: 149-152 (2001).
32. De Siervi A, Parera VE, Batlle A & Rossetti MV. Two new mutations (H106P and
L178V) in the protoporphyrinogen oxidase gene in Argentinean patients with variegate
porphyria. Human Mutation MPR #181 (on line) (2000).
33. De Siervi A, Weiss Cádiz DE, Parera VE, Batlle A & Rossetti MV. Identification and
characterization of two novel mutations that produce Acute Intermittent Porphyria: a 3
base deletion (841-843delGGA) and a missense mutation (T35M). Human Mutation
MIB #370 (on line) (2000).
34. Mendez M, Rossetti MV, De Siervi A, Batlle A & Parera VE. Mutations in familial
Porphyria Cutanea Tarda: two novel and two previously described for
hepatoeritropoietic porphyria. Human Mutation. MIB #354 (on line) (2000).
35. De Siervi A, Parera VE, Varela LS, Batlle A & Rossetti MV. A novel mutation
(1320InsT) identified in two Argentine families with Variegate Porphyria. Human
Mutation. MPR #140 (on line) (2000).
9
36. De Siervi A, Mendez M, Parera VE, Varela LS, Batlle A & Rossetti MV. Acute
Intermittent Porphyria: characterization of two novel mutations in the Porphobilinogen
deaminase gene, one aminoacid deletion (453-455delAGC) and one splicing aceptor
site mutation (IVS8-1G>T). Human Mutation. MIB #271 (on line); 14(4):355 (1999).
37. De Siervi A, Rossetti MV, Parera VE, Mendez M, Varela LS & Batlle A. Acute
intermittent porphyria: Biochemical and clinical analysis in the Argentinean population.
Clinica Chimica Acta 288:63-71 (1999).
38. De Siervi A, Rossetti MV, Parera VE, Astrin KH, Aizencang GI, Glass IA, Batlle A &
Desnick RJ. Identification and characterization of hydroxymethylbylane synthase
mutations causing acute intermittent porphyria: Evidence for an ancestral founder of
the common G111R mutation. American Journal of Medical Genetics. 86:366-375
(1999).
39. De Siervi A, Rossetti MV, Lezama D & Batlle A. Porphyrin biosynthesis in normal and
Haem mutants of S. cerevisiae. Studies about the inheritance of the Hem R +
phenotype. Comparative Biochemistry and Physiology. 115B(2):167-173 (1996).
International and national meetings
She presented more than 150 publications at national and international
meetings.
10

Adriana De Siervi

Transcripción

Documentos relacionados

Rubén Echeverría CIAT Carlos Casamiquela MAGyP Ricardo Mena

posters neurotransmitters, neuromodulators and receptors nr

Allemani 1050 def